Francesco Segrado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Segrado has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Sabina Sieri
Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
7 shared publications - Claudia Agnoli
Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy
6 shared publications Adalberto Cavalleri
4 shared publicationsElisabetta Venturelli
4 shared publications- Elisabetta Venturelli
Nutrition Research and Metabolomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy
4 shared publications - Valeria Pala
Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
4 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 41
Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability
Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quantifying interleudin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, and adiponectin in historical biobank samples with limited volumes and varying plasma anticoagulants. Methods: Luminex-MAGPIX platform was used to evaluate three analytical aspects. Single-well precision was assessed via intra- and inter-assay coefficients of variability (CVs). Plasma matrix effects were examined by pairwise comparison of analyte concentrations across citrate, heparin, and EDTA plasma from 10 volunteers. Cytokine stability was tested after one freeze-thaw cycle (analysis of variance). Results: Single-well measurements showed good precision (CV <10% intra-assay, <15% inter-assay). Plasma matrix affected absolute concentrations. In particular, all analytes were lower in citrate than in EDTA and heparin, but relative relationships and subject-specific rankings remained preserved. Pearson correlation coefficients for IL-6, leptin, and adiponectin were high across matrices (r-range = 0.952–0.999), whereas correlations for TNF-α were lower (r-range = 0.897–0.972). Freeze–thaw stability was analyte- and matrix-dependent: leptin remained stable in heparin and EDTA but decreased 9.5% in citrate; adiponectin was stable in citrate but decreased in heparin (−9.0%) and EDTA (−11.8%). IL-6 and TNF-α were unaffected. Conclusion: IL-6, TNF-α, leptin, and adiponectin were accurately quantified using single-well Luminex assays and showed reasonable tolerance to a single freeze–thaw cycle, offering a practical strategy for preserving valuable specimens. Although plasma anticoagulant affected absolute concentrations, the preservation of relative analyte rankings permits their use in most study designs but limit absolute value comparisons.
- 24 June 2026
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 41
Open AccessLuminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability
Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quantifying interleudin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, and adiponectin in historical biobank samples with limited volumes and varying plasma anticoagulants. Methods: Luminex-MAGPIX platform was used to evaluate three analytical aspects. Single-well precision was assessed via intra- and inter-assay coefficients of variability (CVs). Plasma matrix effects were examined by pairwise comparison of analyte concentrations across citrate, heparin, and EDTA plasma from 10 volunteers. Cytokine stability was tested after one freeze-thaw cycle (analysis of variance). Results: Single-well measurements showed good precision (CV <10% intra-assay, <15% inter-assay). Plasma matrix affected absolute concentrations. In particular, all analytes were lower in citrate than in EDTA and heparin, but relative relationships and subject-specific rankings remained preserved. Pearson correlation coefficients for IL-6, leptin, and adiponectin were high across matrices (r-range = 0.952–0.999), whereas correlations for TNF-α were lower (r-range = 0.897–0.972). Freeze–thaw stability was analyte- and matrix-dependent: leptin remained stable in heparin and EDTA but decreased 9.5% in citrate; adiponectin was stable in citrate but decreased in heparin (−9.0%) and EDTA (−11.8%). IL-6 and TNF-α were unaffected. Conclusion: IL-6, TNF-α, leptin, and adiponectin were accurately quantified using single-well Luminex assays and showed reasonable tolerance to a single freeze–thaw cycle, offering a practical strategy for preserving valuable specimens. Although plasma anticoagulant affected absolute concentrations, the preservation of relative analyte rankings permits their use in most study designs but limit absolute value comparisons.
- Open Access
Investigating Variability in Metabolomics: A Comparative Study of Analytical Platforms and Blood Matrices Using HPLC-HRMS
Untargeted metabolomics faces significant challenges in standardization due to variability introduced by sample preparation and analytical workflows. We systematically evaluated the impact of biological matrices, extraction protocols, and chromatographic configurations to establish a mechanism-informed framework aimed at improving reproducibility in large-scale clinical and epidemiological studies. Three extraction protocols were compared using an in-house pooled heparin plasma: monophasic protein precipitation with isopropanol (IPA), methanol:acetonitrile (MeOH:ACN), and a modified Matyash biphasic method. The most reproducible protocol was then applied to four blood matrices. Samples were analysed using untargeted metabolomics on hydrophilic interaction liquid chromatography (HILIC) and reversed-phase (RP) HPLC columns, with mass spectrometry data processed using Compound Discoverer. Both IPA and MeOH:ACN extractions achieved over 80% of features with coefficient of variation (CV%) ≤ 30% for both RP and HILIC, whereas the Matyash method showed higher variability, with a larger proportion of metabolites exhibiting CV% > 30%. Across matrices, RP chromatography detected over 80% of metabolites with CV% < 30%, while HILIC showed higher variability, with at least 20% of metabolites above this threshold. Among matrices, serum and heparin plasma outperformed EDTA and citrate in reproducibility. We propose a standardized workflow in which monophasic extractions combined with RP chromatography maximize reproducibility and metabolite coverage, minimizing methodological artefacts and providing a reliable framework for robust biological discovery in large-scale untargeted metabolomics studies.
Open AccessInvestigating Variability in Metabolomics: A Comparative Study of Analytical Platforms and Blood Matrices Using HPLC-HRMS
Untargeted metabolomics faces significant challenges in standardization due to variability introduced by sample preparation and analytical workflows. We systematically evaluated the impact of biological matrices, extraction protocols, and chromatographic configurations to establish a mechanism-informed framework aimed at improving reproducibility in large-scale clinical and epidemiological studies. Three extraction protocols were compared using an in-house pooled heparin plasma: monophasic protein precipitation with isopropanol (IPA), methanol:acetonitrile (MeOH:ACN), and a modified Matyash biphasic method. The most reproducible protocol was then applied to four blood matrices. Samples were analysed using untargeted metabolomics on hydrophilic interaction liquid chromatography (HILIC) and reversed-phase (RP) HPLC columns, with mass spectrometry data processed using Compound Discoverer. Both IPA and MeOH:ACN extractions achieved over 80% of features with coefficient of variation (CV%) ≤ 30% for both RP and HILIC, whereas the Matyash method showed higher variability, with a larger proportion of metabolites exhibiting CV% > 30%. Across matrices, RP chromatography detected over 80% of metabolites with CV% < 30%, while HILIC showed higher variability, with at least 20% of metabolites above this threshold. Among matrices, serum and heparin plasma outperformed EDTA and citrate in reproducibility. We propose a standardized workflow in which monophasic extractions combined with RP chromatography maximize reproducibility and metabolite coverage, minimizing methodological artefacts and providing a reliable framework for robust biological discovery in large-scale untargeted metabolomics studies.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Supplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Supplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Background:Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls.Methods:To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis.Results:For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk.Conclusions:Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms.Impact:Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Background:Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls.Methods:To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis.Results:For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk.Conclusions:Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms.Impact:Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Supplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Supplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
- Open Access
- 29 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71279
Explorative Detection of Fractional Exhaled Nitric Oxide ( FeNO ) in Exhaled Breath of Patients With Breast Cancer
Background: Nitric oxide (NO), a gaseous messenger with pleiotropic functions, plays a role in cancer, including breast cancer (BC). Considering the high permeability and leakiness of NO across tissues and the increased levels of NO recently reported in exhaled breath and blood of patients with lung cancer, we explored exhaled NO levels in patients with BC in a future perspective of non‐invasive cancer detection. Patients and Methods: Fractional exhaled NO (FeNO) levels were detected in the breath of 192 women with BC and malignancy‐free controls employing a widely used point‐of‐care (POC)‐based system previously developed for asthma monitoring. Results: FeNO levels were lower in BC patients compared to controls, with the lowest levels in women with HER2‐expressing tumors. In univariate and multivariate analyses and after adjustment for age, smoking, and asthma, this difference was not significant. The effects of smoking were not statistically significant, whereas asthmatic subjects had significantly higher levels of FeNO ( p = 0.006). Neither menopause nor BMI had a significant impact on FeNO levels. Conclusion: Our explorative work indicates that FeNO levels are heterogeneously detected in the breath of BC patients in the absence of confounding effects and are associated with the clinical characteristics of the disease. More sensitive detection of exhaled NO and larger cohorts enriched with ER negative BC are needed to further explore the potential of NO in non‐invasive detection of BC, either alone or in conjunction with other BC‐related volatile markers, and extending the NO measurement to blood or tissues.
- 29 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71279
Open AccessExplorative Detection of Fractional Exhaled Nitric Oxide ( FeNO ) in Exhaled Breath of Patients With Breast Cancer
Background: Nitric oxide (NO), a gaseous messenger with pleiotropic functions, plays a role in cancer, including breast cancer (BC). Considering the high permeability and leakiness of NO across tissues and the increased levels of NO recently reported in exhaled breath and blood of patients with lung cancer, we explored exhaled NO levels in patients with BC in a future perspective of non‐invasive cancer detection. Patients and Methods: Fractional exhaled NO (FeNO) levels were detected in the breath of 192 women with BC and malignancy‐free controls employing a widely used point‐of‐care (POC)‐based system previously developed for asthma monitoring. Results: FeNO levels were lower in BC patients compared to controls, with the lowest levels in women with HER2‐expressing tumors. In univariate and multivariate analyses and after adjustment for age, smoking, and asthma, this difference was not significant. The effects of smoking were not statistically significant, whereas asthmatic subjects had significantly higher levels of FeNO ( p = 0.006). Neither menopause nor BMI had a significant impact on FeNO levels. Conclusion: Our explorative work indicates that FeNO levels are heterogeneously detected in the breath of BC patients in the absence of confounding effects and are associated with the clinical characteristics of the disease. More sensitive detection of exhaled NO and larger cohorts enriched with ER negative BC are needed to further explore the potential of NO in non‐invasive detection of BC, either alone or in conjunction with other BC‐related volatile markers, and extending the NO measurement to blood or tissues.
- Open Access
- 31 October 2022
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 37 (4) , 368-376
A software-assisted untargeted liquid chromatography–mass spectrometry method for lipidomic profiling of human plasma samples
Introduction: In this paper, an analytical pipeline designed for untargeted lipidomic profiling in human plasma is proposed. The analytical pipeline was developed for case-control studies nested in prospective cohorts. Methods: The procedure consisted of isopropanol protein precipitation followed by reverse phase liquid chromatography coupled to high resolution mass spectrometry and software-assisted data processing. The compounds are putatively annotated by matching experimental mass spectrometry data with spectral library data using LipidSearch software. The lipid profile of a pool of plasma samples from 10 healthy volunteers was detected in both positive and negative polarity modes. The impact of the chosen polarity on the number and quality of the lipid identification has been evaluated. Results: More than 1000 lipids from 12 different classes were detected, 1150 in positive mode and 273 in negative mode. Nearly half of them were unambiguously identified by the software in positive mode, and about one-third in negative mode. The method repeatability was assessed on the plasma pool samples by means of variance components analysis. The intra- and inter-assay precision was measured for 10 lipids chosen among the most abundant found within the different lipid classes. The intra-assay coefficients of variation ranged from 2.56% to 4.56% while intra- and inter-day coefficients of variance never exceeded the 15% benchmark adopted. The lipidomic profiles of the 10 healthy volunteers were also investigated. Discussion: This method detects a wide range of lipids and reports their degree of identification. It is particularly fit and well-designed for large case-control epidemiologic studies.
- 31 October 2022
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 37 (4) , 368-376
Open AccessA software-assisted untargeted liquid chromatography–mass spectrometry method for lipidomic profiling of human plasma samples
Introduction: In this paper, an analytical pipeline designed for untargeted lipidomic profiling in human plasma is proposed. The analytical pipeline was developed for case-control studies nested in prospective cohorts. Methods: The procedure consisted of isopropanol protein precipitation followed by reverse phase liquid chromatography coupled to high resolution mass spectrometry and software-assisted data processing. The compounds are putatively annotated by matching experimental mass spectrometry data with spectral library data using LipidSearch software. The lipid profile of a pool of plasma samples from 10 healthy volunteers was detected in both positive and negative polarity modes. The impact of the chosen polarity on the number and quality of the lipid identification has been evaluated. Results: More than 1000 lipids from 12 different classes were detected, 1150 in positive mode and 273 in negative mode. Nearly half of them were unambiguously identified by the software in positive mode, and about one-third in negative mode. The method repeatability was assessed on the plasma pool samples by means of variance components analysis. The intra- and inter-assay precision was measured for 10 lipids chosen among the most abundant found within the different lipid classes. The intra-assay coefficients of variation ranged from 2.56% to 4.56% while intra- and inter-day coefficients of variance never exceeded the 15% benchmark adopted. The lipidomic profiles of the 10 healthy volunteers were also investigated. Discussion: This method detects a wide range of lipids and reports their degree of identification. It is particularly fit and well-designed for large case-control epidemiologic studies.
- Open Access
- 4 March 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (6) , 1209-1215
Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Background: Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls. Methods: To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis. Results: For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk. Conclusions: Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms. Impact: Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.
- 4 March 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (6) , 1209-1215
Open AccessPrediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort
Background: Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls. Methods: To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis. Results: For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk. Conclusions: Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms. Impact: Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.